Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-01-30
2007-01-30
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S014800, C514S015800, C514S016700, C514S017400, C514S018700, C514S019300, C514S563000, C530S300000, C530S327000, C530S328000, C530S329000, C530S330000, C530S331000
Reexamination Certificate
active
10955006
ABSTRACT:
The invention relates to pharmaceutical compounds and compositions comprised of a chemical moiety attached to an opioid such as oxycodone in a manner that substantially decreases the potential of the opioid to cause overdose. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent. Further the compounds and compositions of the invention are useful in preventing addiction and susceptibility to addiction.
REFERENCES:
patent: 3843696 (1974-10-01), Wagner et al.
patent: 3846399 (1974-11-01), Hirschmann et al.
patent: 3878187 (1975-04-01), Schneider et al.
patent: 3884898 (1975-05-01), Schneider
patent: 3975342 (1976-08-01), Gross
patent: 3998799 (1976-12-01), Bodor et al.
patent: 4025501 (1977-05-01), Leute
patent: 4040907 (1977-08-01), Ullman et al.
patent: 4346166 (1982-08-01), Montag et al.
patent: 4356166 (1982-10-01), Peterson et al.
patent: 4399121 (1983-08-01), Albarella et al.
patent: 4427660 (1984-01-01), Schiffman et al.
patent: 4457907 (1984-07-01), Porter
patent: 4552864 (1985-11-01), Antoni et al.
patent: 4650675 (1987-03-01), Borel et al.
patent: 4730048 (1988-03-01), Portoghese
patent: 4801575 (1989-01-01), Pardridge
patent: 4863735 (1989-09-01), Kohn et al.
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 4960790 (1990-10-01), Stella et al.
patent: 4976962 (1990-12-01), Bichon et al.
patent: 5026827 (1991-06-01), Miyazaki
patent: 5073641 (1991-12-01), Bundgaard et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5183883 (1993-02-01), Tanaka et al.
patent: 5219564 (1993-06-01), Zalipsky et al.
patent: 5238714 (1993-08-01), Wallace et al.
patent: 5362831 (1994-11-01), Mongelli et al.
patent: 5534496 (1996-07-01), Lee et al.
patent: 5610283 (1997-03-01), Buechler
patent: 5618926 (1997-04-01), Salamone et al.
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5762909 (1998-06-01), Uzgiris
patent: 5767227 (1998-06-01), Latham et al.
patent: 5846743 (1998-12-01), Janmey et al.
patent: 5851536 (1998-12-01), Yager et al.
patent: 5863899 (1999-01-01), Cheronis et al.
patent: 5882645 (1999-03-01), Toth et al.
patent: 5891459 (1999-04-01), Cooke et al.
patent: 5898033 (1999-04-01), Swadesh et al.
patent: 5910569 (1999-06-01), Latham et al.
patent: 5948750 (1999-09-01), Garsky et al.
patent: 5952294 (1999-09-01), Lazo et al.
patent: 5977163 (1999-11-01), Li et al.
patent: 6005004 (1999-12-01), Katz et al.
patent: 6030941 (2000-02-01), Summerton et al.
patent: 6043230 (2000-03-01), Arimilli et al.
patent: 6048736 (2000-04-01), Kosak
patent: 6074659 (2000-06-01), Kunz et al.
patent: 6075120 (2000-06-01), Cheronis et al.
patent: 6093391 (2000-07-01), Kabanov et al.
patent: 6235718 (2001-05-01), Balasubramanium
patent: 6255285 (2001-07-01), Kotake
patent: 6306993 (2001-10-01), Rothbard et al.
patent: 6309633 (2001-10-01), Ekwuribe et al.
patent: 6458842 (2002-10-01), Dickinson et al.
patent: 6716452 (2004-04-01), Piccariello et al.
patent: 6740641 (2004-05-01), Gao et al.
patent: 6784186 (2004-08-01), Jackson
patent: 7060708 (2006-06-01), Piccariello et al.
patent: 2001/0031873 (2001-10-01), Greenwald et al.
patent: 2002/0059013 (2002-05-01), Rajala et al.
patent: 2002/0098999 (2002-07-01), Gallop et al.
patent: 2002/0099013 (2002-07-01), Piccariello et al.
patent: 2002/0151526 (2002-10-01), Gallop et al.
patent: 2002/0151529 (2002-10-01), Cundy et al.
patent: 2004/0058946 (2004-03-01), Buchwald et al.
patent: 2004/0180036 (2004-09-01), Ashton et al.
patent: 2004/0204434 (2004-10-01), Shafer
patent: 2005/0038121 (2005-02-01), Mickle et al.
patent: 2005/0054561 (2005-03-01), Mickle et al.
patent: 2005/0065086 (2005-03-01), Mickle et al.
patent: 2005/0069550 (2005-03-01), Mickle et al.
patent: 2005/0074425 (2005-04-01), Waugh et al.
patent: 2005/0080012 (2005-04-01), Mickle et al.
patent: 2005/0112088 (2005-05-01), Zhao et al.
patent: 2005/0176644 (2005-08-01), Mickle et al.
patent: 2005/0176645 (2005-08-01), Mickle et al.
patent: 2005/0176646 (2005-08-01), Mickle et al.
patent: 2005/0266070 (2005-12-01), Mickle et al.
patent: 2006/0014697 (2006-01-01), Mickle et al.
patent: WO 94/11021 (1994-05-01), None
patent: WO 00/37103 (2000-06-01), None
patent: WO 2004-064839 (2004-08-01), None
patent: WO 2004-082620 (2004-09-01), None
patent: WO 2005-118642 (2005-12-01), None
patent: WO 2006-059106 (2006-06-01), None
Chapter 1. The Controlled Substances Act. DEA. Web document <http://www.dea.gov/pubs/abuse/1-csa.htm>, 18 pages; accessed Apr. 28, 2006.
Aggarwal, et al., “Synthesis and Biological Evaluation of Prodrugs of Zidovudine,”J. Med. Chem.,33(5):1505-1511 (1990).
Amidon, G., et al., “A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation ofin VitroDrug Product Dissolution andin VivoBioavailability,”Pharmaceutical Research,vol. 12, No. 3 (1995).
Balimane, P., et al., “Effect of Ionization on the Variable Uptake of Valacyclovir via the Human Intestinal Peptide Transporter (hPepT1) in CHP cells,”Biopharm Drug Dispos,21(5):165-174 (2000), Abstract.
Balimane, P.V., et al., “Direct Evidence for Peptide Transporter (PepT1)-Mediated Uptake of a Nonpeptide Prodrug, Valacyclovir,”Biochem Biophys Res Commun,250(2):246-251 (1998), Abstract.
Bunevicius, R., “Effects of Thyroxine as Compared with Thyroxine Plus Triiodothyronine in Patients with Hypothyroidism,”The New England Journal of Medicine,vol. 340, No. 6 (1999).
Burnette, Thimysta C., et al., “Metabolic Disposition of the Acyclovir Prodrug Valaciclovir in the Rat,”Drug Metabolism and Disposition,22(1):60-64 (1994).
Canaris, G., “The Colorado Thyroid Disease Prevalence Study,” Archives Internal Medicine Articles and Abstracts, vol. 160, No. 4 (2000).
De Vrueh, Remco L.A., et al, “Transport of L-Valine-Acyclovir Via the Oligopeptide Transporter in the Human Intestinal Cell Line, Caco-2,”Journal of Pharmacology and Experimental Therapeutics,286(2): 1166-1170 (1988).
Friedrichsen, G.M., et al., “Model Prodrugs Designed for the Intestinal Peptide Transporter. A Synthetic Approach for Coupling of Hydroxy-Containing Compounds to Dipeptides,”Eur J Pharm Sci,14(1):13-19 (2001, Abstract.
Guo, A., et al., “Interactions of a Nonpeptidic Drug. Valacyclovir, with the Human Intestinal Peptide Transporter (hPEPT1) Expressed in a Mammalian Cell Line,”Pharmacol Exp Ther,289(1):448-454 (1999), Abstract.
Han H., et al., “5'-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT and Absorbed by the Intestinal PEPT1 Peotide Transporter,”Pharm Res,15(8):1154-1159 (1998), Abstract.
Han, H.K., et al., “Cellular Uptake Mechanism of Amino Acid Ester prodrugs in Caco-2hPEPT1 Cells Overexpressing a Human Peptide Transporter,”Pharm Res,15(9):1382-1386 (1998), Abstract.
Han, Hyo-Kyung, et al., “Targeted Prodrug Design to Optimize Drug Delivery,”AAPS PharmSci,2(1): Article 6 (2000).
Havranova, Marie et al., “A High-Molecular Mass Derivative of Trypsin-Kallikrein Inhibitor for Potential Medical Use, II,”Hoppe-Seyler's Z. Physiol. Chem.,363:295-303 (1982).
Hosztafi, S. et al. “Synthesis and Analgetic Activity of Nicotinic Esters of Morphine Derivatives,” Arzneim.-Forsch./Drug Res. 43(II), Nr. 11 (1993).
International Search Report, dated Oct. 9, 2003, for PCT/US03/05525.
International Search Report, dated Sep. 3, 2003.
Knutter, I. et al., “A Novel Inhibitor of the Mammalian Peptide Transporter PEPT1,”Biochemistry,40(14):4454-4458 (2001), Abstract.
Kovacs, J., et al., “Glutamic and Aspartic Anhydrides. Rearrangement of N-Carboxyglutamic 1,5-Anhydride to the Leuchs' Anhydride and Conversion of the Latter to Pyroglutamic Acid,”.
Kramer, Werner et al., “Intestinal Absorption of Peptides by Coupling to Bile Acids,”The Journal of Biochemistry,269(14):10621-10627 (1994).
Leibach, F.H. et al., “Peptide Transporters in the Intestine and the Kidney
Bera Sanjib
Guenther Sven
Hirschelman Wendy
Krishnan Suma
Lauderback Christopher
Hunton & Williams LLP
Kosar Andrew D.
New River Pharmaceuticals Inc.
Tsang Cecilia J.
LandOfFree
Compounds and compositions for prevention of overdose of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and compositions for prevention of overdose of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and compositions for prevention of overdose of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3748711